Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
LOS ANGELES, April 04, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq:PETX) concerning possible violations of federal securities laws between March 16, 2015 and February 3, 2017 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm by the April 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, Aratana made false and/or misleading statements and/or failed to disclose: that the Company did not have manufacturing contracts in place sufficient to support manufacturing of its appetite stimulation drug ENTYCE at a commercial scale; ENTYCE was not likely to be commercially available until late 2017; the Company had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and that as a result of the above, Aratana’s public statements were materially false and misleading at all relevant times.
On February 6, 2017, the Company disclosed that the Center for Veterinary Medicine requested more information about ENTYCE. Aratana told investors that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.” When this news was announced to the public, the value of Aratana stock declined, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
